| Intervention | Comparator | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Placebo | Placebo + MTX | aTNF | TOF 5mg | TCZ | ABT + MTX | ANA + MTX | aTNF + MTX | TOF 5mg + MTX | TCZ + MTX | ||
| Placebo | OR (95% CrI) |
1.00 (1,1) |
0.27 (0.04, 1.80) |
0.15 (0.06, 0.33) |
0.20 (0.05, 0.83) |
0.06 (0.02, 0.24) |
0.07 (0.01, 0.47) |
0.11 (0.01, 1.01) |
0.05 (0.01, 0.35) |
0.06 (0.01, 0.46) |
0.05 (0.01, 0.29) |
| P(better) | NA | 0.08 | < 0.01 | 0.01 | < 0.01 | 0.01 | 0.03 | < 0.01 | < 0.01 | < 0.01 | |
| Placebo + MTX | OR (95% CrI) |
3.66 (0.56, 26.40) |
1.00 (1, 1) |
0.56 (0.10, 3.17) |
0.74 (0.07, 8.55) |
0.24 (0.06, 0.88) |
0.24 (0.14, 0.41) |
0.41 (0.13, 1.25) |
0.19 (0.13, 0.27) |
0.22 (0.11, 0.44) |
0.19 (0.09, 0.41) |
| P(better) | 0.92 | NA | 0.23 | 0.39 | 0.02 | < 0.01 | 0.05 | < 0.01 | < 0.01 | < 0.01 | |
| aTNF | OR (95% CrI) |
6.65 (3.05, 15.43) |
1.80 (0.32, 10.07) |
1.00 (1, 1) |
1.34 (0.25, 7.07) |
0.43 (0.14, 1.26) |
0.43 (0.07, 2.62) |
0.74 (0.09, 5.64) |
0.35 (0.06, 1.95) |
0.40 (0.06, 2.59) |
0.34 (0.07, 1.54) |
| P(better) | > 0.99 | 0.77 | NA | 0.64 | 0.05 | 0.16 | 0.37 | 0.10 | 0.15 | 0.07 | |
| TOF 5mg | OR (95% CrI) |
4.98 (1.21, 21.62) |
1.36 (0.12, 14.42) |
0.75 (0.14, 3.95) |
1.00 (1, 1) |
0.32 (0.04, 2.31) |
0.33 (0.03, 3.75) |
0.55 (0.04, 7.56) |
0.26 (0.02, 2.89) |
0.30 (0.02, 3.63) |
0.26 (0.03, 2.47) |
| P(better) | 0.99 | 0.61 | 0.36 | NA | 0.12 | 0.17 | 0.32 | 0.13 | 0.16 | 0.11 | |
| TCZ | OR (95% CrI) |
15.51 (4.12, 62.04) |
4.20 (1.14, 15.56) |
2.34 (0.80, 7.05) |
3.13 (0.43, 23.22) |
1.00 (1, 1) |
1.01 (0.24, 4.14) |
1.72 (0.30, 9.58) |
0.82 (0.20, 3.06) |
0.93 (0.22, 4.12) |
0.81 (0.28, 2.25) |
| P(better) | > 0.99 | 0.98 | 0.95 | 0.88 | NA | 0.51 | 0.75 | 0.37 | 0.46 | 0.32 | |
| ABT + MTX | OR (95% CrI) |
15.25 (2.13, 122.40) |
4.15 (2.43, 7.19) |
2.30 (0.38, 14.49) |
3.04 (0.27, 38.72) |
0.99 (0.24, 4.12) |
1.00 (1, 1) |
1.71 (0.48, 5.92) |
0.80 (0.45, 1.38) |
0.92 (0.41, 2.16) |
0.79 (0.31, 2.05) |
| P(better) | 0.99 | > 0.99 | 0.84 | 0.83 | 0.49 | NA | 0.81 | 0.20 | 0.42 | 0.30 | |
| ANA + MTX | OR (95% CrI) |
8.95 (0.99, 87.80) |
2.44 (0.80, 7.81) |
1.35 (0.18, 10.59) |
1.80 (0.13, 26.84) |
0.58 (0.10, 3.35) |
0.59 (0.17, 2.09) |
1.00 (1, 1) |
0.47 (0.14, 1.53) |
0.54 (0.15, 2.12) |
0.47 (0.12, 1.85) |
| P(better) | 0.97 | 0.95 | 0.63 | 0.68 | 0.25 | 0.19 | NA | 0.09 | 0.17 | 0.12 | |
| aTNF + MTX | OR (95% CrI) |
18.83 (2.85, 148.01) |
5.16 (3.74, 7.53) |
2.85 (0.51, 17.67) |
3.79 (0.35, 47.14) |
1.22 (0.33, 4.94) |
1.24 (0.73, 2.23) |
2.11 (0.65, 7.05) |
1.00 (1, 1) |
1.15 (0.59, 2.42) |
0.98 (0.44, 2.36) |
| P(better) | > 0.99 | > 0.99 | 0.90 | 0.87 | 0.63 | 0.80 | 0.91 | NA | 0.66 | 0.48 | |
| TOF 5mg + MTX | OR (95% CrI) |
16.47 (2.19, 129.20) |
4.49 (2.25, 8.70) |
2.51 (0.39, 15.67) |
3.30 (0.28, 42.02) |
1.07 (0.24, 4.60) |
1.08 (0.46, 2.46) |
1.84 (0.47, 6.79) |
0.87 (0.41, 1.68) |
1.00 (1, 1) |
0.86 (0.30, 2.33) |
| P(better) | > 0.99 | > 0.99 | 0.85 | 0.84 | 0.54 | 0.58 | 0.83 | 0.34 | NA | 0.38 | |
| TCZ + MTX | OR (95% CrI) |
19.23 (3.45, 114.60) |
5.22 (2.45, 11.39) |
2.90 (0.65, 13.75) |
3.86 (0.41, 38.66) |
1.24 (0.44, 3.61) |
1.26 (0.49, 3.24) |
2.14 (0.54, 8.43) |
1.02 (0.42, 2.29) |
1.16 (0.43, 3.33) |
1.00 (1, 1) |
| P(better) | > 0.99 | > 0.99 | 0.93 | 0.89 | 0.68 | 0.70 | 0.88 | 0.52 | 0.62 | NA | |
ABT = abatacept; ACR50 = 50% improvement in American College of Rheumatology criteria; ANA = anakinra; aTNF = anti-tumor necrosis factor; CrI = credible interval; mg = milligram; MTX = methotrexate; NA = not applicable; OR = odds ratio; P(better) = probability that treatment (in row) is showing greater response than comparator (in column); TCZ = tocilizumab; TOF = tofacitinib.